Giant Lymph Node Hyperplasia (Castleman's Disease)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
GLUT- 1S| Expression
KR0100984 KCCH/RR-045/2000 A Study on Activation of FDG-PET Use GLUT- 1S| Expression The FDG Uptake and GLUT-1 Expression of the Mediastinal Nodes in the Non-Small Cell Lung Cancer IV ^Hl^ FDG ^41^ Glucose Transporter(GLUT-l)^ Expression''^] ^ 2000. 12. 31. : % 5) •1- fi I. FDG Glucose Transporter (GLUT-1) Expression n. FDG ^^1- Glucose Transporter^ FDG o.s FDG-PET m. S.x4.$\ FDG ^i FDG-PET1- anti-Glut-1 antibodyS immunohistostaining*l-^4. H^ 317](mm), ^^ follicle ^^ KGrade 1-4), ^5.^ follicle^ 'g^ ^^(1-4), IV. Al PET # ^• test, P=0.07). *>fl^fe- PET ^ ^H^^ follicle leveH °1 ^^fe FDG Hl^r GLUT- iHS^S. ^1-afl FDG ^ follicular hyperplasia^ V. FDG ^ -ffe FDG-PET^l 6.4 FDG GLUT-1 l- fe GLUT-1 ^^) FDG ^ PET FDG -2- SUMMARY 1. Project Title The FDG uptake and glucose transporter(GLUT-l) expression of the mediastinal nodes in the non-small cell lung cancer 2. Objective and Importance of the Project FDG-PET scan provides physiologic and metabolic information that characterizes lesions that are indeterminate by CT and that accurately stages the distribution of lung cancer. Many authors reported that mediastinal staging of non-small-cell lung cancer was improved markedly by FDG-PET in addition to CT, but the problem of false positive and negative N2 was not overcome completely. The aim of this study was. to understand the mechanism of FDG uptake in the mediastinal nodes, and improve the accuracy of mediastinal staging of non-small cell lung cancer by PET. -
Microlymphatic Surgery for the Treatment of Iatrogenic Lymphedema
Microlymphatic Surgery for the Treatment of Iatrogenic Lymphedema Corinne Becker, MDa, Julie V. Vasile, MDb,*, Joshua L. Levine, MDb, Bernardo N. Batista, MDa, Rebecca M. Studinger, MDb, Constance M. Chen, MDb, Marc Riquet, MDc KEYWORDS Lymphedema Treatment Autologous lymph node transplantation (ALNT) Microsurgical vascularized lymph node transfer Iatrogenic Secondary Brachial plexus neuropathy Infection KEY POINTS Autologous lymph node transplant or microsurgical vascularized lymph node transfer (ALNT) is a surgical treatment option for lymphedema, which brings vascularized, VEGF-C producing tissue into the previously operated field to promote lymphangiogenesis and bridge the distal obstructed lymphatic system with the proximal lymphatic system. Additionally, lymph nodes with important immunologic function are brought into the fibrotic and damaged tissue. ALNT can cure lymphedema, reduce the risk of infection and cellulitis, and improve brachial plexus neuropathies. ALNT can also be combined with breast reconstruction flaps to be an elegant treatment for a breast cancer patient. OVERVIEW: NATURE OF THE PROBLEM Clinically, patients develop firm subcutaneous tissue, progressing to overgrowth and fibrosis. Lymphedema is a result of disruption to the Lymphedema is a common chronic and progres- lymphatic transport system, leading to accumula- sive condition that can occur after cancer treat- tion of protein-rich lymph fluid in the interstitial ment. The reported incidence of lymphedema space. The accumulation of edematous fluid mani- varies because of varying methods of assess- fests as soft and pitting edema seen in early ment,1–3 the long follow-up required for diagnosing lymphedema. Progression to nonpitting and irre- lymphedema, and the lack of patient education versible enlargement of the extremity is thought regarding lymphedema.4 In one 20-year follow-up to be the result of 2 mechanisms: of patients with breast cancer treated with mastec- 1. -
Disease Discovery Classification of Lymphoid Neoplasms
From www.bloodjournal.org by on December 4, 2008. For personal use only. 2008 112: 4384-4399 doi:10.1182/blood-2008-07-077982 Classification of lymphoid neoplasms: the microscope as a tool for disease discovery Elaine S. Jaffe, Nancy Lee Harris, Harald Stein and Peter G. Isaacson Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/cgi/content/full/112/12/4384 Articles on similar topics may be found in the following Blood collections: Neoplasia (4200 articles) Free Research Articles (544 articles) ASH 50th Anniversary Reviews (32 articles) Clinical Trials and Observations (2473 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published semimonthly by the American Society of Hematology, 1900 M St, NW, Suite 200, Washington DC 20036. Copyright 2007 by The American Society of Hematology; all rights reserved. From www.bloodjournal.org by on December 4, 2008. For personal use only. ASH 50th anniversary review Classification of lymphoid neoplasms: the microscope as a tool for disease discovery Elaine S. Jaffe,1 Nancy Lee Harris,2 Harald Stein,3 and Peter -
M. H. RATZLAFF: the Superficial Lymphatic System of the Cat 151
M. H. RATZLAFF: The Superficial Lymphatic System of the Cat 151 Summary Four examples of severe chylous lymph effusions into serous cavities are reported. In each case there was an associated lymphocytopenia. This resembled and confirmed the findings noted in experimental lymph drainage from cannulated thoracic ducts in which the subject invariably devdops lymphocytopenia as the lymph is permitted to drain. Each of these patients had com munications between the lymph structures and the serous cavities. In two instances actual leakage of the lymphography contrrult material was demonstrated. The performance of repeated thoracenteses and paracenteses in the presenc~ of communications between the lymph structures and serous cavities added to the effect of converting the. situation to one similar to thoracic duct drainage .The progressive immaturity of the lymphocytes which was noted in two patients lead to the problem of differentiating them from malignant cells. The explanation lay in the known progressive immaturity of lymphocytes which appear when lymph drainage persists. Thankful acknowledgement is made for permission to study patients from the services of Drs. H. J. Carroll, ]. Croco, and H. Sporn. The graphs were prepared in the Department of Medical Illustration and Photography, Dowristate Medical Center, Mr. Saturnino Viloapaz, illustrator. References I Beebe, D. S., C. A. Hubay, L. Persky: Thoracic duct 4 Iverson, ]. G.: Phytohemagglutinin rcspon•e of re urctcral shunt: A method for dccrcasingi circulating circulating and nonrecirculating rat lymphocytes. Exp. lymphocytes. Surg. Forum 18 (1967), 541-543 Cell Res. 56 (1969), 219-223 2 Gesner, B. M., J. L. Gowans: The output of lympho 5 Tilney, N. -
Original Article Igm Expression in Paraffin Sections Distinguishes Follicular Lymphoma from Reactive Follicular Hyperplasia
Int J Clin Exp Pathol 2014;7(6):3264-3271 www.ijcep.com /ISSN:1936-2625/IJCEP0000379 Original Article IgM expression in paraffin sections distinguishes follicular lymphoma from reactive follicular hyperplasia Yuanyuan Zheng, Xiaoge Zhou, Jianlan Xie, Hong Zhu, Shuhong Zhang, Yanning Zhang, Xuejing Wei, Bing Yue Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Received March 30, 2014; Accepted May 21, 2014; Epub May 15, 2014; Published June 1, 2014 Abstract: The trapping of IgM-containing immune complexes (ICs) by follicular dendritic cells (FDCs) serves as an important step in promoting germinal center (GC) formation. Thus, the deposition of IgM-containing ICs on FDCs can be detected by antibodies recognizing IgM. The present investigation provides the first comprehensive report on the IgM staining pattern in follicular lymphoma (FL, n = 60), with comparisons to reactive follicular hyperplasias (RFH, n = 25), demonstrating that immunohistochemical staining for IgM in paraffin-embedded sections seems to be an additional tool for differentiating between FL and RFH. In RFH, IgM highlighted processes of FDCs, with stronger and more compact staining in light than in dark zones, with occasional very dim staining of GC B cells. In FL, IgM expres- sion patterns were of three types. Pattern I (38 cases) stained tumor cells within neoplastic follicles, with no staining of FDCs. Pattern II (15 cases) stained neither tumor cells nor FDCs. Pattern III (7 cases) stained tumor cells with (3 cases) or without (4 cases) IgM expression; however, variable and attenuated IgM expression was observed on FDCs in each case. Interestingly, significant numbers of IgD+ mantle cells were preserved around the neoplastic follicles in these 7 cases. -
LIST of OCCUPATIONAL DISEASES (Revised 2010)
LIST OF OCCUPATIONAL DISEASES (revised 2010) Identification and recognition of occupational diseases: Criteria for incorporating diseases in the ILO list of occupational diseases Occupational Safety and Health Series, No. 74 List of occupational diseases (revised 2010) Identification and recognition of occupational diseases: Criteria for incorporating diseases in the ILO list of occupational diseases INTERNATIONAL LABOUR OFFICE • GENEVA Copyright © International Labour Organization 2010 First published 2010 Publications of the International Labour Office enjoy copyright under Protocol 2 of the Universal Copyright Convention. Nevertheless, short excerpts from them may be reproduced without authorization, on condition that the source is indicated. For rights of reproduction or translation, application should be made to ILO Publications (Rights and Permissions), International Labour Office, CH-1211 Geneva 22, Switzerland, or by email: pubdroit@ ilo.org. The International Labour Office welcomes such applications. Libraries, institutions and other users registered with reproduction rights organizations may make copies in accordance with the licences issued to them for this purpose. Visit www.ifrro.org to find the reproduction rights organization in your country. ILO List of occupational diseases (revised 2010). Identification and recognition of occupational diseases: Criteria for incorporating diseases in the ILO list of occupational diseases Geneva, International Labour Office, 2010 (Occupational Safety and Health Series, No. 74) occupational disease / definition. 13.04.3 ISBN 978-92-2-123795-2 ISSN 0078-3129 Also available in French: Liste des maladies professionnelles (révisée en 2010): Identification et reconnaissance des maladies professionnelles: critères pour incorporer des maladies dans la liste des maladies professionnelles de l’OIT (ISBN 978-92-2-223795-1, ISSN 0250-412x), Geneva, 2010, and in Spanish: Lista de enfermedades profesionales (revisada en 2010). -
ICD-10 International Statistical Classification of Diseases and Related Health Problems
ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision Volume 2 Instruction manual 2010 Edition WHO Library Cataloguing-in-Publication Data International statistical classification of diseases and related health problems. - 10th revision, edition 2010. 3 v. Contents: v. 1. Tabular list – v. 2. Instruction manual – v. 3. Alphabetical index. 1.Diseases - classification. 2.Classification. 3.Manuals. I.World Health Organization. II.ICD-10. ISBN 978 92 4 154834 2 (NLM classification: WB 15) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. -
FAQ REGARDING DISEASE REPORTING in MONTANA | Rev
Disease Reporting in Montana: Frequently Asked Questions Title 50 Section 1-202 of the Montana Code Annotated (MCA) outlines the general powers and duties of the Montana Department of Public Health & Human Services (DPHHS). The three primary duties that serve as the foundation for disease reporting in Montana state that DPHHS shall: • Study conditions affecting the citizens of the state by making use of birth, death, and sickness records; • Make investigations, disseminate information, and make recommendations for control of diseases and improvement of public health to persons, groups, or the public; and • Adopt and enforce rules regarding the reporting and control of communicable diseases. In order to meet these obligations, DPHHS works closely with local health jurisdictions to collect and analyze disease reports. Although anyone may report a case of communicable disease, such reports are submitted primarily by health care providers and laboratories. The Administrative Rules of Montana (ARM), Title 37, Chapter 114, Communicable Disease Control, outline the rules for communicable disease control, including disease reporting. Communicable disease surveillance is defined as the ongoing collection, analysis, interpretation, and dissemination of disease data. Accurate and timely disease reporting is the foundation of an effective surveillance program, which is key to applying effective public health interventions to mitigate the impact of disease. What diseases are reportable? A list of reportable diseases is maintained in ARM 37.114.203. The list continues to evolve and is consistent with the Council of State and Territorial Epidemiologists (CSTE) list of Nationally Notifiable Diseases maintained by the Centers for Disease Control and Prevention (CDC). In addition to the named conditions on the list, any occurrence of a case/cases of communicable disease in the 20th edition of the Control of Communicable Diseases Manual with a frequency in excess of normal expectancy or any unusual incident of unexplained illness or death in a human or animal should be reported. -
Follicular Lymphoid Hyperplasia of the Posterior Maxillary Site Presenting
Watanabe et al. BMC Oral Health (2019) 19:243 https://doi.org/10.1186/s12903-019-0936-9 CASE REPORT Open Access Follicular lymphoid hyperplasia of the posterior maxillary site presenting as uncommon entity: a case report and review of the literature Masato Watanabe* , Ai Enomoto, Yuya Yoneyama, Michihide Kohno, On Hasegawa, Yoko Kawase-Koga, Takafumi Satomi and Daichi Chikazu Abstract Background: Follicular lymphoid hyperplasia (FLH) is characterized by an increased number and size of lymphoid follicles. In some cases, the etiology of FLH is unclear. FLH in the oral and maxillofacial region is an uncommon benign entity which may resemble malignant lymphoma clinically and histologically. Case presentation: We report the case of a 51-year-old woman who presented with an asymptomatic firm mass in the left posterior maxillary site. Computed tomography scan of her head and neck showed a clear circumscribed solid mass measuring 28 × 23 mm in size. There was no evidence of bone involvement. Incisional biopsy demonstrated benign lymphoid tissue. The patient underwent complete surgical resection. Histologically, the resected specimen showed scattered lymphoid follicles with germinal centers and predominant small lymphocytes in the interfollicular areas. Immunohistochemically, the lymphoid follicles were positive for CD20, CD79a, CD10, CD21, and Bcl6. The germinal centers were negative for Bcl2. Based on these findings, a diagnosis of benign FLH was made. There was no recurrence at 1 year postoperatively. Conclusions: We diagnosed an extremely rare case of FLH arising from an unusual site and whose onset of entity is unknown. Careful clinical and histopathological evaluations are essential in making a differential diagnosis from a neoplastic lymphoid proliferation with a nodular growth pattern. -
3. Ellis GL. Lymphoid Lesions of Salivary Glands: Malignant And
Med Oral Patol Oral Cir Bucal. 2007 Nov 1;12(7):E479-85. Lymphoid lesions of salivary glands Lymphoid lesions of salivary glands: Malignant and Benign Gary L. Ellis D.D.S. Adjunct Professor, University of Utah School of Medicine. Director, Oral & Maxillofacial Pathology. ARUP Laboratories. Salt Lake City, Utah, USA Correspondence: Gary L. Ellis, D.D.S. 500 Chipeta Way Salt Lake City, UT, USA E-mail: [email protected] Received: 20-05-2007 Ellis GL. Lymphoid lesions of salivary glands: Malignant and Benign. Accepted: 10-06-2007 Med Oral Patol Oral Cir Bucal. 2007 Nov 1;12(7):E479-85. © Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946 Indexed in: -Index Medicus / MEDLINE / PubMed -EMBASE, Excerpta Medica -SCOPUS -Indice Médico Español -IBECS ABSTRACT Lesions of salivary glands with a prominent lymphoid component are a heterogeneous group of diseases that include benign reactive lesions and malignant neoplasms. Occasionally, these pathologic entities present difficulties in the clinical and pathological diagnosis and prognosis. Lymphoepithelial sialadenitis, HIV-associated salivary gland disease, chronic sclerosing sialadenitis, Warthin tumor, and extranodal marginal zone B-cell lymphoma are examples of this pathology that are sometimes problematic to differentiate from one another. In this paper the author reviewed the main clinical, pathological and prognostic features of these lesions. Key words: Lymphoepithelial sialadenitis, HIV-associated salivary gland disease, chronic sclerosing sialadenitis, Warthin tumor, extranodal marginal zone B-cell lymphoma. INTRODUCTION tion of disease, and disease is often confined to the salivary Lymphocytic infiltrates of the major salivary glands are glands. Because normal parotid glands contain intra-paren- involved in a spectrum of diseases that range from reactive chymal nodal tissue, some parotid lymphomas have a nodal to benign and malignant neoplasms. -
Overexpression of Glut1 in Lymphoid Follicles Correlates with False-Positive 18F-FDG PET Results in Lung Cancer Staging
Overexpression of Glut1 in Lymphoid Follicles Correlates with False-Positive 18F-FDG PET Results in Lung Cancer Staging Jin-Haeng Chung, MD1; Kyung-Ja Cho, MD2; Seung-Sook Lee, MD1; Hee Jong Baek, MD3; Jong-Ho Park, MD3; Gi Jeong Cheon, MD4; Chang-Woon Choi, MD4; and Sang Moo Lim, MD4 1Department of Pathology, Korea Cancer Center Hospital, Seoul, Korea; 2Department of Pathology, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea; 3Department of Thoracic Surgery, Korea Cancer Center Hospital, Seoul, Korea; and 4Department of Nuclear Medicine, Korea Cancer Center Hospital, Seoul, Korea The evaluation of mediastinal lymph node involvement in non- Increased glucose uptake is one of the major metabolic small cell lung carcinoma (NSCLC) is very important for the changes found in malignant tumors (1), a process that is selection of surgical candidates. PET using 18F-FDG has re- mediated by glucose transporters (Gluts) (2). On the basis of markably improved mediastinal staging in NSCLC. However, this relationship, PET using 18F-FDG has been widely used false 18F-FDG PET results remain a problem. This study was for the detection of primary and metastatic tumors in on- undertaken to identify histologic and immunohistochemical dif- 18 ferences between cases showing false and true results of me- cology patients (3). It is known that F-FDG PET is useful diastinal lymph node involvement assessed by 18F-FDG PET. and superior to CT for the nodal staging of non-small cell Methods: Preoperative 18F-FDG PET examinations were per- lung carcinoma (NSCLC) (4,5). However, FDG is not a formed on 62 patients with NSCLC, and mediastinal lymph node very tumor-specific substance, and benign lesions with in- sampling was done at thoracotomy or mediastinoscopy. -
Lymphadenopathy in Rheumatic Patients
Ann Rheum Dis: first published as 10.1136/ard.46.3.224 on 1 March 1987. Downloaded from Annals of the Rheumatic Diseases, 1987; 46, 224-227 Lymphadenopathy in rheumatic patients C A KELLY, A J MALCOLM, AND I GRIFFITHS From the Departments of Rheumatology and Pathology, Royal Victoria Infirmary, Newcastle upon Tyne SUMMARY Lymph node biopsy specimens from 22 patients with chronic inflammatory joint disease have been studied. The histology has been reviewed and immunoperoxidase staining carried out for the major immunoglobulin heavy and light chains, macrophage markers, and MT1, MB1 surface markers. Although two of these patients had been initially diagnosed and treated for malignant lymphoma, the clinical course has not substantiated the diagnosis, and on review malignancy could not be identified in any of the biopsy specimens. Careful attention to specific histological features, together with adequate clinical information, is therefore essential if the true nature of the lymph node enlargement is to be recognised. Clinical review of the 22 patients suggested that lymphadenopathy may, in some cases, be an early feature of inflammatory polyarthritis, and this was supported by the observation that 20% of patients with otherwise unexplained reactive lymphadenopathy developed an inflammatory polyarthropathy within one year of biopsy. Key words: lymphoma, rheumatoid arthritis, immunoglobulins. copyright. Lymph node enlargement often causes clinical the mean age of the group was 54 years (range 38-75 concern, especially when it is associated with sys- years), with a mean disease duration of seven years temic symptoms such as weight loss, anaemia, and (range one month to 20 years). Two patients had malaise.